Trial Profile
Study to assess whether treatment with GC811007 would arrest the decline in renal function and the associated progression of diabetic retinopathy, peripheral neuropathy and autonomic neuropathy in patients with Type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Trientine (Primary)
- Indications Diabetic nephropathies; Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms INFO-RENAL
- Sponsors Protemix Corporation
- 25 Sep 2012 New trial record